Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Fuzionaire Theranostics Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals sector. Prosecution is currently limited to 1 distinct examiner and 1 distinct art unit. This indicates a specific administrative footprint at the patent office for the company's current filings. With only this pending action, the company can dedicate significant attention to the specific legal and technical issues raised in the matter.
JONES, DAMERON LEVEST is identified as the busiest examiner, holding 1 pending office action. This individual manages the company's active office actions within the Biotechnology & Pharmaceuticals area. Success in this technology area depends on navigating the specific requirements of JONES, DAMERON LEVEST and the associated 1 distinct art unit. The outcome of this single interaction will determine the immediate progress of the company's patent applications.
Because there is only 1 pending office action, the company's prosecution profile is highly centralized. Practitioners should focus on the specific feedback provided by the examiner to ensure the claims meet the standards of the assigned unit. This active matter represents the current focus of the company's efforts to secure patent protection in the pharmaceutical field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JONES, DAMERON LEVEST | 1 | 67.8% | +31.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18304302 | Theranostic Silicon-Fluoride Heteroaromatic Systems and Methods Thereof | JONES, DAMERON LEVEST | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18304302 | Theranostic Silicon-Fluoride Heteroaromatic Systems and Methods Thereof | JONES, DAMERON LEVEST | 1618 | §112 | Non-Final OA | — | Pending | Apr 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFuzionaire Theranostics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dameron Levest Jones has the most, with 1 of Fuzionaire Theranostics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
